Past Conference
Explore key agenda highlights, top speakers, and industry insights from the 2026 Conference.
Conference Co-Chairs
Melissa Mannion
Of Counsel
Jones Day
Former Senior Regulatory Counsel, CDER Office of Generic Drug Policy, FDA
Without a doubt, ACI’s FDA Boot Camp Conference is the foundational Food and Drug Law conference! FDA Boot Camp will equip attendees with the essential knowledge they need to further explore the vast and intricate Food and Drug Law space, and it is the springboard to other, more focused ACI conference offerings.
Kurt Karst
Director
Hyman, Phelps & McNamara, P.C.
With all that is happening this year in the FDA space, having several former FDA leaders on faculty for the 2026 FDA Boot Camp will bring invaluable insight and practical guidance to help attendees navigate the Agency and effectively manage FDA-related issues and challenges.
Former FDA Officials to Speak
Laura Akowuah
Special Counsel
Cooley LLP
Former Acting Director, Office of Enforcement, Human Foods Program; Former, Associate Chief Counsel for Enforcement, Office of the Chief Counsel, FDA
Jennifer L. Bragg
Partner
Latham & Watkins LLP
Former Associate Chief Counsel for Enforcement, FDA
Elizabeth Jungman
Partner
Hogan Lovells
Former Chief of Staff; Associate Director for Policy, CDER, FDA
Maarika Kimbrell
Partner
Morgan, Lewis & Bockius LLP
Former Director, Office of New Drug Policy, OND, CDER, FDA
Seth A. Mailhot
Partner
Barnes & Thornburg LLP
Former Compliance Officer, FDA
Samantha Hong
Partner
Kleinfeld Kaplan Becker LLP
Former Associate Chief Counsel, Office of the Chief Counsel, FDA
Featured Speakers
Brian Burgess
Partner
Goodwin Procter LLP
Former Special Assistant to the Solicitor General, U.S. DOJ
Rachel Turow
Of Counsel, FDA Regulatory
Skadden Arps
Benjamin Zegarelli
Of Counsel
Mintz
Katlin McKelvie
Partner
Gibson Dunn
Former Deputy General Counsel, HHS
Matthew Hegreness
Partner, FDA Regulation
Covington & Burling LLP
Bindu Donovan
Partner
Morrison & Foerster LLP
What’s New in 2026
Get clarity on how the second Trump administration and RFK Jr. are influencing FDA priorities.
Understand the impact of the Commissioner’s National Priority Voucher (CNPV) Pilot on development incentives.
Review FDA’s evolving approach to Complete Response Letters and transparency.
Strengthen your knowledge of core FDA building blocks:
- Approvals for drugs and biologics, clinical trial requirements, cGMPs, labeling, advertising and promotion, enforcement, Hatch-Waxman and BPCIA fundamentals, and more.
Download Brochure
Flip through our past conference brochure and discover the hot topics discussed.